FGF-2 Regulates Cell Proliferation, Migration, and Angiogenesis through an NDY1/KDM2B-miR-101-EZH2 Pathway

The histone H3K27 methyltransferase EZH2 plays an important role in oncogenesis, by mechanisms that are incompletely understood. Here, we show that the JmjC domain histone H3 demethylase NDY1 synergizes with EZH2 to silence the EZH2 inhibitor miR-101. NDY1 and EZH2 repress miR-101 by binding its pro...

Full description

Saved in:
Bibliographic Details
Published inMolecular cell Vol. 43; no. 2; pp. 285 - 298
Main Authors Kottakis, Filippos, Polytarchou, Christos, Foltopoulou, Parthena, Sanidas, Ioannis, Kampranis, Sotirios C., Tsichlis, Philip N.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 22.07.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The histone H3K27 methyltransferase EZH2 plays an important role in oncogenesis, by mechanisms that are incompletely understood. Here, we show that the JmjC domain histone H3 demethylase NDY1 synergizes with EZH2 to silence the EZH2 inhibitor miR-101. NDY1 and EZH2 repress miR-101 by binding its promoter in concert, via a process triggered by upregulation of NDY1. Whereas EZH2 binding depends on NDY1, the latter binds independently of EZH2. However, both are required to repress transcription. NDY1 and EZH2 acting in concert upregulate EZH2 and stabilize the repression of miR-101 and its outcome. NDY1 is induced by FGF-2 via CREB phosphorylation and activation, downstream of DYRK1A, and mediates the FGF-2 and EZH2 effects on cell proliferation, migration, and angiogenesis. The FGF-2-NDY1/EZH2-miR-101-EZH2 axis described here was found to be active in bladder cancer. These data delineate an oncogenic pathway that functionally links FGF-2 with EZH2 via NDY1 and miR-101. [Display omitted] ► Pathway linking FGF-2 with epigenetic regulation of gene expression ► NDY1 upregulation triggers the binding of EZH2 and NDY1 to the miR-101 locus ► Activation of this pathway is essential for the biology elicited by FGF-2 ► The pathway is active in normal cells, tumor cell lines, and primary tumors
Bibliography:http://dx.doi.org/10.1016/j.molcel.2011.06.020
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1097-2765
1097-4164
DOI:10.1016/j.molcel.2011.06.020